Jetema (KOSDAQ 216080) 2026 stock outlook. A deep look at the domestic approval catalyst for The Toxin botulinum product, Epitique HA filler export growth, the strain-origin question, the FDA and China NMPA option value, and how Jetema stacks up against Hugel, Daewoong (Nabota), Medytox and Pharmaresearch.
Humedix (KRX: 200670) 2026 stock outlook, analyzed qualitatively. A hyaluronic-acid platform spans a defensive prescription cash cow — the Hyruan osteoarthritis knee injection — and a cyclical aesthetics growth engine in Elravie dermal fillers, plus toxin expansion, CDMO, and Huons Group distribution. We weigh the moat, the China NMPA export lever, and the competitive risks from LG Chem, Hugel and Jetema.
Medytox (KRX 086900) Stock Outlook 2026 covering the Meditoxin, Coretox and Newlux botulinum toxin lineup, hyaluronic acid fillers, China approval and US expansion, the Daewoong strain lawsuit and regulatory risk, a Korean toxin peer comparison, and what global investors should watch.
A qualitative 2026 stock outlook for Pharma Research (KRX 214450), the Korean aesthetics-bio company behind Rejuran, a salmon-DNA PN/PDRN skin booster. We cover its brand moat, expansion into fillers, toxin, and cosmetics, high margins, the growth-premium valuation risk, competition from Hugel and others, overseas approval hurdles, and how global investors should frame the KRW-listed shares.
Hugel (KRX 145020) 2026 stock outlook. A deep qualitative analysis of its botulinum toxin (Botulax/Letybo) and HA filler (The Chaeum) business, the US FDA approval and American aesthetics market entry, China and Europe expansion, the GS Group consortium acquisition, the toxin strain-origin litigation risk, and how a Korean challenger competes against the global Big 3.